NASDAQ:PACB - Pacific Biosciences of California Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $43.50
  • Forecasted Upside: 46.27 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.59 (2.02%)

This chart shows the closing price for PACB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacific Biosciences of California Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PACB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PACB

Analyst Price Target is $43.50
▲ +46.27% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pacific Biosciences of California in the last 3 months. The average price target is $43.50, with a high forecast of $62.00 and a low forecast of $15.00. The average price target represents a 46.27% upside from the last price of $29.74.

This chart shows the closing price for PACB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Pacific Biosciences of California. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2021Morgan StanleyBoost Price TargetEqual Weight$12.00 ➝ $45.00Low
2/11/2021Cantor FitzgeraldBoost Price TargetIn-Line ➝ Overweight$45.00 ➝ $62.00Low
2/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$20.00 ➝ $52.00Low
1/15/2021Piper SandlerBoost Price TargetNeutral$12.00 ➝ $20.00Medium
1/12/2021Cantor FitzgeraldBoost Price TargetReduce ➝ Overweight$25.00 ➝ $45.00Medium
12/8/2020Cantor FitzgeraldBoost Price TargetOverweight$16.00 ➝ $25.00Low
11/4/2020Morgan StanleyBoost Price TargetEqual Weight$7.00 ➝ $12.00High
11/3/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00High
10/13/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $17.00High
10/2/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00Low
10/1/2020Piper SandlerBoost Price TargetOverweight$6.00 ➝ $12.00High
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$7.00Low
6/10/2020Cantor FitzgeraldReiterated RatingBuy$5.00High
6/1/2020Cantor FitzgeraldInitiated CoverageBuy$5.00High
5/7/2020Piper SandlerLower Price TargetOverweight$7.00 ➝ $6.00Medium
4/17/2020Cantor FitzgeraldReiterated RatingOverweightMedium
3/9/2020Cantor FitzgeraldReiterated RatingOverweight$5.00Medium
12/18/2019Piper Jaffray CompaniesReiterated RatingBuy$7.00Low
10/15/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$8.00High
6/20/2019Cantor FitzgeraldSet Price TargetHold$8.00Low
6/13/2019Cantor FitzgeraldReiterated RatingHoldLow
5/3/2019Cantor FitzgeraldReiterated RatingHold$8.00Low
4/2/2019StephensDowngradeOverweight ➝ Equal Weight$4.50 ➝ $8.00Low
1/4/2019CowenDowngradeOutperform ➝ Market PerformLow
11/12/2018Cantor FitzgeraldDowngradeOverweight ➝ Neutral$8.00Low
11/1/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
10/21/2018Cantor FitzgeraldReiterated RatingBuy$8.00Low
10/19/2018CowenInitiated CoverageOutperform ➝ Outperform$6.50High
10/11/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
8/8/2018Cantor FitzgeraldInitiated CoverageOverweight$5.00High
8/3/2018Piper Jaffray CompaniesReiterated RatingHold$3.80High
11/3/2017First AnalysisDowngradeOverweight ➝ Equal Weight$4.00N/A
9/28/2017CL KingDowngradeBuy ➝ Neutral$6.80High
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00Medium
2/3/2017Cantor FitzgeraldReiterated RatingBuy$8.00N/A
12/18/2016Cantor FitzgeraldSet Price TargetBuy$8.00N/A
12/16/2016Cantor FitzgeraldReiterated RatingOverweight$15.00N/A
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$12.00N/A
11/3/2016Cantor FitzgeraldLower Price TargetBuy$18.00 ➝ $15.00N/A
10/24/2016Cantor FitzgeraldSet Price TargetBuy$18.00N/A
6/29/2016Cantor FitzgeraldReiterated RatingBuy$18.00N/A
6/27/2016CL KingInitiated CoverageBuy$11.00N/A
(Data available from 6/21/2016 forward)
Pacific Biosciences of California logo
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $29.74
Low: $28.23
High: $29.88

50 Day Range

MA: $27.87
Low: $22.30
High: $33.64

52 Week Range

Now: $29.74
Low: $3.35
High: $53.69


1,886,028 shs

Average Volume

3,900,306 shs

Market Capitalization

$5.90 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Pacific Biosciences of California?

The following sell-side analysts have issued stock ratings on Pacific Biosciences of California in the last year: Cantor Fitzgerald, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for PACB.

What is the current price target for Pacific Biosciences of California?

4 Wall Street analysts have set twelve-month price targets for Pacific Biosciences of California in the last year. Their average twelve-month price target is $43.50, suggesting a possible upside of 49.2%. Cantor Fitzgerald has the highest price target set, predicting PACB will reach $62.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $15.00 for Pacific Biosciences of California in the next year.
View the latest price targets for PACB.

What is the current consensus analyst rating for Pacific Biosciences of California?

Pacific Biosciences of California currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PACB will outperform the market and that investors should add to their positions of Pacific Biosciences of California.
View the latest ratings for PACB.

What other companies compete with Pacific Biosciences of California?

How do I contact Pacific Biosciences of California's investor relations team?

Pacific Biosciences of California's physical mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is 650-521-8000 and its investor relations email address is [email protected] The official website for Pacific Biosciences of California is